Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro is expected to reduce appetite, yet some people find they are still eating too much on Mounjaro — especially in the first few weeks, or after a dose increase. Clinical trial data show that appetite suppression varies between individuals and tends to strengthen as the dose rises; if hunger feels unchanged at 2.5 mg, that is not a sign the medicine is failing. These are prescription-only medicines, and a GPhC-registered prescriber will review your progress at every repeat to ensure your dose and plan are working together. The sections below draw on SURMOUNT-1, published in the New England Journal of Medicine, and NHS clinical guidance to explain why overeating on tirzepatide happens, what drives it, and what tends to help.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial enrolled around 2,500 adults with obesity and followed them for 72 weeks. Across the trial, average body-weight reduction reached roughly 20–21% at the 15 mg dose. What the raw efficacy numbers do not always convey is that appetite suppression was dose-dependent: participants' sense of fullness and reduction in cravings built gradually as the titration schedule progressed, rather than arriving in full on the first injection.
This matters if you are in the early weeks and feel you are eating as much as before. The 2.5 mg starting dose is designed primarily to let your body adjust to the medicine (particularly the gastrointestinal effects) not to produce its maximum effect on hunger. You can expect appetite changes to become more noticeable from 5 mg upwards, and again at each subsequent step, though timing differs from person to person.
The NHS patient information for tirzepatide notes that the medicine works alongside a reduced-calorie diet and increased activity; it is not designed to override food intake entirely. If your hunger feels largely unchanged, tell your prescriber at your next review rather than waiting, that feedback is clinically useful.
Mounjaro targets the biological signals that drive physical hunger: it slows how quickly the stomach empties and influences the brain's appetite centres via two gut-hormone pathways. For many people, this produces a clear, noticeable reduction in the urge to eat.
What it does not automatically change is habitual eating, reaching for food out of boredom, stress, habit or social pressure rather than genuine hunger. These patterns are deeply ingrained and persist independently of stomach fullness. You might find your physical hunger drops but you still open the fridge at 10 pm because that has been your routine for years.
Recognising the difference is practically useful. Before eating, a brief pause to ask whether you are actually hungry or responding to a cue (the clock, a stressful email, the smell of someone else's lunch) can interrupt the habitual loop. Building that awareness is not about willpower; it is about noticing something the medicine has not yet addressed. Our guide to eating on Mounjaro covers practical approaches to food choices and meal structure that tend to support the medicine's effect.
Protein and fibre also play a role here. Both slow digestion and extend satiety, which reinforces the effect tirzepatide is already trying to produce. Prioritising them at each meal (rather than relying on the medicine to do all the work) is something many people find makes a meaningful difference once they are a few doses in.
Occasional overeating (at a celebration, after a stressful week, or when you miss a dose) is not a cause for concern. But if you are consistently consuming substantially more than a reduced-calorie intake allows, and this is happening week after week, it is worth examining a few possibilities.
First, are your meals structured? Some people on tirzepatide find their appetite falls so unevenly through the day that they under-eat at breakfast and lunch, then feel genuinely hungry and less in control by evening. Spreading protein and fibre across three meals tends to smooth this out. Our Mounjaro eating plan page goes into meal structure in more detail.
Second, are you eating enough overall? There is a separate risk on this medicine of eating far too little, especially in the first few weeks of each dose increase. If you are restricting significantly during the day, rebound hunger later is predictable. The risks of eating too few calories on Mounjaro are worth understanding alongside this.
Third, consider whether the dose has had long enough to settle. Titration typically happens in four-week steps; appetite effects often consolidate in the third or fourth week of a new dose, not the first. Patience across that window, combined with keeping a brief food diary, can show patterns that are genuinely informative.
If none of this accounts for what you are experiencing, raise it directly with your prescriber. On the cost side, understanding what the medicine's price reflects in the UK private market can help you plan if you are considering staying on it longer-term while your dose adjusts.
Eating slowly matters more on Mounjaro than many people expect. Because gastric emptying is already slower, fullness signals arrive later than the food does, eating quickly means you can easily consume more than you need before your brain registers that you have had enough. Putting cutlery down between bites sounds elementary, but the people who find it hardest to stop overeating on tirzepatide are often those who eat at pace.
Plate size and food environment are worth adjusting too. Research in behavioural nutrition consistently shows that people eat to their plate rather than their hunger, a smaller plate, pre-portioned food, and keeping snack foods out of the immediate environment all reduce automatic overeating without requiring ongoing mental effort.
One detail that fits naturally into a morning routine: keeping your pen in the fridge door and taking it on the same day each week means you are less likely to miss a dose, which matters because a missed injection can briefly reduce the medicine's appetite effect. Consistency with the injection schedule is a practical lever that is easy to underestimate.
For a comprehensive picture of what and how to eat while on tirzepatide, the guide to what to eat on Mounjaro and the full Mounjaro treatment overview are both worth reading before your next review. If you are still finding appetite management difficult and have not yet started treatment, a free consultation with our prescribers is the place to begin, they can assess whether Mounjaro is right for you and discuss what to expect at each stage of titration.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.